With first-in-human studies for emodepside in healthy volunteers successfully completed, preparations are underway to run a Phase II clinical trial at two sites in Ghana. In the Democratic Republic of Congo, training and trial site renovations are advancing ahead of a Phase II proof-of-concept study for TylAMac, which was shown to be safe and well-tolerated in Phase I studies. And new efforts to identify novel treatments against ‘nematode’ worms have kicked off following the launch of a new multidisciplinary consortium: the Helminth Elimination Platform (HELP).
Health Policy Watch [10 January 2020]
“Mental health – among the ‘most neglected’ of neglected tropical disease issues, says DNDi scientist”
Vet-Magazin [2 December 2019]
“HELP-Konsortium entwickelt neue Medikamente gegen parasitäre Wurminfektionen” – “HELP consortium develops new drugs against parasitic worm infections”
8-12 December 2019
Cape Town, South Africa
- Sabine Specht, Head of Filarial Clinical Programme – session on helminths drug development
Genf – 28. November 2019
Ein neues Konsortium bestehend aus Forschungsinstituten, Universitäten, gemeinnützigen Organisationen und Pharmaunternehmen hat sich zusammengeschlossen, um neue Medikamente gegen Infektionen verursacht durch parasitäre Würmer (Helminthen) zu entwickeln. Zu diesen Krankheiten zählen die Flussblindheit und lymphatische Filariose sowie Infektionen mit Haken- und Peitschenwürmern. Fast eine Milliarde Menschen weltweit sind betroffen.
Geneva – 28 November 2019
“Pan-nematode” drug development platform is part of Europe’s Horizon 2020 programme
A new consortium of research institutes, universities, not-for-profit organizations, and pharmaceutical companies has teamed up to develop novel drugs for infections caused by parasitic worms (helminths), a debilitating group of diseases that includes river blindness, lymphatic filariasis, as well as infection with hookworm and whipworm, which together affect close to a billion people.
Geneva/Seattle – 25 November 2019
DNDi has been awarded $29.2 million to accelerate the development of innovative new drugs for patients in sub-Saharan Africa with sleeping sickness (human African trypanosomiasis – $15 million) and river blindness (onchocerciasis – $14.2 million) by the Bill & Melinda Gates Foundation These two parasitic diseases could be eliminated if new patient care tools are brought to bear.
Washington DC, USA – 20 November 2019
Over four million people will be infected with river blindness in 2025 in areas where African eye worm is present, according to new modelling
Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or ‘African eye worm’, according to a study published in Clinical Infectious Diseases.
Health Policy Watch [20 November 2019]
“African eye worm threatens efforts to eliminate river blindness”
ETHealthWorld [12 November 2019]
“Lymphatic filariasis needs wider audience and greater awareness: Dr Suman Rijal”
68th Annual Meeting
20-24 November 2019
National Harbor, USA
- Symposium on tools to accelerate elimination of onchocerciasis
- Presentations on onchocerciasis, lymphatic filariasis, leishmaniasis, clinical trials, and Chagas disease.
This book includes information on the common approaches and the most important factors that lead to the development of new drugs for treating tropical diseases.
Wiley, July 2019
by Vinkeles Melchers NVS, Coffeng LE, Boussinesq M, Pedrique B, Pion SDS, Tekle AH, Zouré HGM, Wanji S, Remme JH, Stolk WA.
Clinical Infectious Diseases, July 2019
23-27 June 2019
- Poster presentation on onchocerciasis
Two Phase I studies in healthy volunteers for potentially macrofilaricidal drugs were successfully completed, for emodepside (Bayer) and the antibiotic TylAMac (AbbVie). Phase II studies are planned for sub-Saharan Africa.
Ghana News Agency [30 January 2019]
“UHAS broadens institutional collaborations”
India Science Wire [24 January 2019]
“Snakebite: a public health problem you don’t hear of”
India Science Wire [24 January 2019]
“एक दशक में मिल सकती है काला अजार के उपचार की नयी थेरेपी” – “Snakebite: a public health problem you don’t hear of”
This special series highlights regional public health programme successes, and explores issues that still need supportive policy and research.
BMJ, January 2019